

# Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P56B1E128AEEN.html>

Date: January 2020

Pages: 104

Price: US\$ 2,000.00 (Single User License)

ID: P56B1E128AEEN

## Abstracts

Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2020, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. PWS is due to lack of several genes on one of an individual's two chromosome 15's. In the majority of cases, there is a deletion. In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15's from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 5, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor

projects.

The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Prader-Willi Syndrome (PWS) - Overview

Prader-Willi Syndrome (PWS) - Therapeutics Development

Prader-Willi Syndrome (PWS) - Therapeutics Assessment

Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development

Prader-Willi Syndrome (PWS) - Drug Profiles

Prader-Willi Syndrome (PWS) - Dormant Projects

Prader-Willi Syndrome (PWS) - Discontinued Products

Prader-Willi Syndrome (PWS) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Auris Medical Holding Ltd, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Benuvia Therapeutics Inc, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Bioprojet SCR, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by ConSynance Therapeutics Inc, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by GLWL Research Inc, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Helsinn Group, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by LG Chem Ltd, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Lipidio Pharmaceuticals Inc, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Millendo Therapeutics Inc, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Neuracle Science Co Ltd, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by OptiNose US Inc, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals Inc, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H1 2020

Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, H1 2020

Prader-Willi Syndrome (PWS) - Dormant Projects, H1 2020

Prader-Willi Syndrome (PWS) - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Auris Medical Holding Ltd  
Benuvia Therapeutics Inc  
Bioprojet SCR  
Chong Kun Dang Pharmaceutical Corp  
ConSynance Therapeutics Inc  
Ferring International Center SA  
GLWL Research Inc  
Helsinn Group  
LG Chem Ltd  
Lipidio Pharmaceuticals Inc  
Millendo Therapeutics Inc  
Neuracle Science Co Ltd  
OptiNose US Inc  
Rhythm Pharmaceuticals Inc  
Saniona AB  
Solenio Therapeutics Inc

## I would like to order

Product name: Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P56B1E128AEEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P56B1E128AEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970